- Home
- RSLS vs OGEN Comparison
RSLS vs OGEN Comparison
Compare RSLS & OGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RSLS
- OGEN
- Stock Information
- Founded
- RSLS 2002
- OGEN 1996
- Country
- RSLS United States
- OGEN United States
- Employees
- RSLS N/A
- OGEN N/A
- Industry
- RSLS Medical/Dental Instruments
- OGEN Biotechnology: Pharmaceutical Preparations
- Sector
- RSLS Health Care
- OGEN Health Care
- Exchange
- RSLS Nasdaq
- OGEN Nasdaq
- Market Cap
- RSLS 4.5M
- OGEN 4.6M
- IPO Year
- RSLS 2007
- OGEN N/A
- Fundamental
- Price
- RSLS $4.31
- OGEN $0.17
- Analyst Decision
- RSLS Hold
- OGEN
- Analyst Count
- RSLS 1
- OGEN 0
- Target Price
- RSLS N/A
- OGEN N/A
- AVG Volume (30 Days)
- RSLS 101.4K
- OGEN 14.1M
- Earning Date
- RSLS 05-21-2025
- OGEN 05-09-2025
- Dividend Yield
- RSLS N/A
- OGEN N/A
- EPS Growth
- RSLS N/A
- OGEN N/A
- EPS
- RSLS N/A
- OGEN N/A
- Revenue
- RSLS $7,175,000.00
- OGEN N/A
- Revenue This Year
- RSLS $52.80
- OGEN N/A
- Revenue Next Year
- RSLS N/A
- OGEN N/A
- P/E Ratio
- RSLS N/A
- OGEN N/A
- Revenue Growth
- RSLS N/A
- OGEN N/A
- 52 Week Low
- RSLS $4.03
- OGEN $0.11
- 52 Week High
- RSLS $414.99
- OGEN $2.52
- Technical
- Relative Strength Index (RSI)
- RSLS 34.73
- OGEN 45.56
- Support Level
- RSLS $4.34
- OGEN $0.11
- Resistance Level
- RSLS $4.95
- OGEN $0.20
- Average True Range (ATR)
- RSLS 0.53
- OGEN 0.03
- MACD
- RSLS 0.19
- OGEN -0.00
- Stochastic Oscillator
- RSLS 10.11
- OGEN 26.67
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.
About OGEN Oragenics Inc.
Oragenics Inc is engaged in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases. The company's product ONP-002 is a fully synthetic, non-naturally occurring neurosteroid, is lipophilic, and can cross the blood-brain barrier to rapidly reduce swelling, oxidative stress and inflammation while restoring proper blood flow through gene amplification. The Company operates in one reportable segment, which includes activities related to advancing the development of its concussion drug, ONP-002.